USFDA issues EIR to Zydus Lifesciences for Pharmez Facility

The EIR report indicates that the inspection is closed.

257
USFDA Inspection
USFDA Inspection

Last Updated on October 2, 2024 by The Health Master

Ahmedabad: Zydus Lifesciences has recently announced that the Company has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for the inspection conducted at its manufacturing facility located at Pharmez, Ahmedabad, from March 20 to 24, 2023.

The inspection has been classified as Voluntary Action Indicated (VAI). The EIR report indicates that the inspection is closed.

Medical Dialogues team had earlier reported that the USFDA had concluded an inspection with three observations at the Company’s said manufacturing facility.

Zydus Lifesciences Limited, formerly known as Cadila Healthcare Limited, is an Indian Pharmaceutical company headquartered in Ahmedabad.

The Company was founded in the year 1952 by Mr. Ramanbhai B. Patel (late), a first-generation entrepreneur and a doyen in the field of Indian Pharmaceuticals. It is primarily engaged in the manufacture of generic drugs.

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon

For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:

YouTube Icon

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos on consumer awareness, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news